https://finance.yahoo.com/news/intelligent-bio-begins-dosing-non-103309318.html
US-based company Intelligent Bio Solutions has completed patient screening and will start dosing and sampling in the pharmacokinetic (PK) study for its fingerprint drug screening technology.
The study is expected to support the planned 510(k) submission to the US FDA, intended for Q4 of this year. Intelligent Bio expects the study to complete recruitment by the end of June, with a review of the PK study results expected to be finalised by the end of next month.
The news comes on the heels of last week’s announcement of the company’s decision to shift its “operating structure from a UK-based model to a global framework”. Intelligent Bio plans to enter the US market with its fingerprint drug screening technology during H1 next year.
The Intelligent fingerprinting drug screening system detects the presence of specific drugs and their metabolites using fingerprint sweat analysis. Using a small, tamper-evident drug screening cartridge, the device can collect ten fingerprint sweat samples in under a minute.
The device aims to identify “current impairment”, not past use, as the test has a detection window of approximately 14–16 hours. The test is intended to be used to check for “fitness for duty” on the day and screen for common drugs of abuse such as cocaine, cannabis, methamphetamine and opiates.
The PK study aims to investigate the levels of opiates in fingerprint sweat compared with blood, oral fluid and urine samples. It will recruit 40 healthy adults and analyse the specimens using validated methods such as liquid chromatography, mass spectrometry and the Intelligent fingerprinting drug screening system.
The use of sweat testing as a method of drug detection is being developed by multiple companies. In February, the US Anti-Doping Agency partnered with Epicore to develop a sweat-sensing technology as a method of drug detection.
Epicore’s wearable sweat-collection device, Discovery Patch, comprises a wearable microfluidic patch that captures eccrine sweat directly from the skin during exercise, environmental exposure and pharmacologic modes of sweat induction. Sweat is transferred from the microfluidic patch to clean lab storage containers using a sweat extraction apparatus designed to rapidly collect and prepare sweat samples for biochemical analysis.
"Intelligent Bio begins dosing for non-invasive drug screening technology" was originally created and published by Medical Device Network, a GlobalData owned brand.
![Bullish](/static/images/ih2-bull.png)
Recent INBS News
- Intelligent Bio Solutions Completes In-Clinic Portion of Pharmacokinetic (PK) Study Part of 510(k) Pathway for Approval & Commences Review of Results • GlobeNewswire Inc. • 06/28/2024 12:30:00 PM
- Intelligent Bio Solutions Expands Presence in the UK Retail Sector with Major Account Acquisitions • GlobeNewswire Inc. • 06/27/2024 12:30:00 PM
- Intelligent Bio Solutions Broadens UK Customer Base by Securing Two Key Accounts with Over 70 Locations and Over 15,000 Employees in the Warehouse and Logistics Sector • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:28:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 09:00:40 PM
- Intelligent Bio Solutions Begins Subject Dosing and Sampling for FDA 510(k) Pharmacokinetic (PK) Study for its Intelligent Fingerprinting Drug Screening Technology • GlobeNewswire Inc. • 06/18/2024 12:30:00 PM
- Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives • GlobeNewswire Inc. • 06/13/2024 12:30:00 PM
- Intelligent Bio Solutions Adds Major European Transport and Infrastructure Solutions Provider to Growing Number of Accounts Adopting Fingerprint Drug Screening Technology • GlobeNewswire Inc. • 06/12/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 09:00:28 PM
- Intelligent Bio Solutions to Participate in the Sidoti Small-Cap Conference on June 12-13, 2024 • GlobeNewswire Inc. • 06/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:00:15 PM
- Intelligent Bio Solutions Successfully Completes Recruitment and Begins Subject Screening for FDA 510(k) Pharmacokinetic (PK) Study • GlobeNewswire Inc. • 05/29/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:20:16 PM
- Intelligent Bio Solutions Unveils Key Performance Indicator Growth in the United Kingdom as Drug Screening Industry Combats Drug Test Cheating and Searches for Simpler, Faster, Non-Invasive and More Cost-Effective Solutions • GlobeNewswire Inc. • 05/23/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 09:00:44 PM
- Innovative Fingerprint Drug Screening Solution Showcased at the UK's Premier Health and Safety Event • GlobeNewswire Inc. • 05/17/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:30:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 12:30:55 PM
- Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights • GlobeNewswire Inc. • 05/08/2024 12:30:00 PM
- Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results • GlobeNewswire Inc. • 04/18/2024 12:30:00 PM
- Intelligent Bio Solutions Subsidiary Broadens Intellectual Property Portfolio with Grant of New European Patent with Unitary Effect for Innovative Intelligent Fingerprinting DSR-Plus Cartridge Reader • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 03/12/2024 11:30:00 PM
- Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 03/11/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/04/2024 10:26:44 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM